MS

Microglia, critical to Alzheimer’s research, can now be produced artificially

The quest for better understanding of Alzheimer’s disease (AD) has a powerful new tool at its disposal — the ability to artificially generate brain cells that have been shown to play an important role in the disease function.

Classified as: microglia, MS, stem cells, Alzheimer's disease, iPSC, Jack Antel, Luke Healy
Published on: 16 May 2017

In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.

Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.

Classified as: Research, The Neuro, Amit Bar-Or, MS, health and lifestyle, Douglas Arnold, ocrelizumab
Category:
Published on: 9 Jan 2017

Drug shown to reduce new attacks/symptom progression in some patients

In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.

Classified as: Multiple Sclerosis, Amit Bar-Or, MS, Douglas Arnold, ocrelizumab
Published on: 22 Dec 2016

A project led by an MNI researcher has been awarded $6.1 million to study progressive multiple sclerosis.

The International Progressive MS Alliance has awarded three $6.1 million Collaborative Network Award grants for a total investment of $18.4 million toward accelerating the pace of progressive MS research. More than 2.3 million people worldwide live with MS and more than one million of those living with the disease have progressive MS.

Classified as: Multiple Sclerosis, MS, Progressive MS, Douglas Arnold
Published on: 20 Sep 2016

McGill Newsroom

3D depth-sensing camera shown to measure walking difficulties

A commonly used device found in living rooms around the world could be a cheap and effective means of evaluating the walking difficulties of multiple sclerosis (MS) patients.

The Microsoft Kinect is a 3D depth-sensing camera used in interactive video activities such as tennis and dancing. It can be hooked up to an Xbox gaming console or a Windows computer.

Classified as: Montreal Neurological Institute and Hospital, Multiple Sclerosis, MS, Microsoft, health and lifestyle, kinect, xbox, Farnood Gholami, Jozsef Kövecses, gait characteristic
Published on: 15 Aug 2016

3D depth-sensing camera shown to measure walking difficulties

A commonly used device found in living rooms around the world could be a cheap and effective means of evaluating the walking difficulties of multiple sclerosis (MS) patients.

The Microsoft Kinect is a 3D depth-sensing camera used in interactive video activities such as tennis and dancing. It can be hooked up to an Xbox gaming console or a Windows computer.

Classified as: engineering, Research, Multiple Sclerosis, MS, daria trojan
Published on: 15 Aug 2016

May 2016 - Multiple Sclerosis Awareness Month

 

Multiple sclerosis treatment and research has long been a focus at the Montreal Neurological Institute and Hospital, known simply as The Neuro, an illustrious member of McGill University and the McGill University Health Centre. Indeed, The Neuro introduced Canada’s first MS clinic. The clinic’s highly specialized staff employs the latest research data and treatment methods in a clinical atmosphere of innovation and progress.

Classified as: neuroscience, Research, Multiple Sclerosis, MS
Category:
Published on: 2 May 2016

A new study led by researchers at the Montreal Neurological Institute and Hospital of McGill University and the MUHC, gets closer to identifying the mechanisms responsible for multiple sclerosis and makes headway in the search for better treatments.

Classified as: Montreal Neurological Institute, Multiple Sclerosis, Amit Bar-Or, MS, B cell depletion therapy, B cell depletion, B cell
Category:
Published on: 23 Oct 2015

Low levels of vitamin D significantly increase the risk of developing multiple sclerosis (MS), according to a study led by Dr. Brent Richards of the Lady Davis Institute at the Jewish General Hospital, and published in PLOS Medicine. This finding, the result of a sophisticated Mendelian randomization analysis, confirms a long-standing hypothesis that low vitamin D is strongly associated with an increased susceptibility to MS. This connection is independent of other factors associated with low vitamin D levels, such as obesity.

Classified as: McGill University, vitamin D, jewish general hospital, Multiple Sclerosis, MS, Brett Richards
Category:
Published on: 25 Aug 2015

The brain is a privileged organ in the body. So vital to life, the brain is protected from alterations elsewhere in the body by a highly regulated gateway known as the blood-brain barrier, which allows only selected molecules to pass through.

Classified as: brain, Research, Multiple Sclerosis, MS, protein, mice, animal, BBB, blood-brain barrier, sclerosis
Published on: 22 Apr 2015

What’s new at The Neuro

Research: B cell study may lead to treatment options for MS

Classified as: neuroscience, brain, neurological, Neuro, Montreal Neurological Institute and Hospital, Multiple Sclerosis, MS, faculty of medicine research
Category:
Published on: 30 Apr 2014

Powerful treatment improves patients’ lives and provides new insight into mechanisms of the disease

Classified as: neuroscience, brain, treatment, neurological, Multiple Sclerosis, Amit Bar-Or, bone marrow, MS, stem cells, transplant
Category:
Published on: 26 Mar 2013